By Fineline Cube 
PegBio Co., Ltd. (HKG: 2565) announced today that it has entered into a non‑binding term sheet with PDC FZ‑LLC of the United Arab Emirates (“PDC”) to grant an exclusive license for its lead GLP‑1 agonist, visepegenatide (PB‑119). The drug is a subcutaneous injectable designed for the treatment of type 2 diabetes mellitus and obesity management.
Deal Highlights
- License Scope – PDC will hold exclusive rights to develop, register, manufacture, and commercialize visepegenatide throughout the Middle East and Africa (MEA).
- Technology Transfer – A full technology transfer package will be provided, covering all manufacturing processes and quality‑control specifications.
- Branding Rights – Visepegenatide will be marketed under a trademark owned by PDC within the licensed territory.
Strategic Rationale
- PegBio – The partnership expands PegBio’s global reach into high‑growth MEA markets, positioning PB‑119 as a first‑in‑class therapeutic for diabetes and obesity.
- PDC – Securing an exclusive, full‑scope license allows PDC to leverage its regional manufacturing and distribution networks, accelerate product launch timelines, and capture a growing demand for GLP‑1 therapies.
Next Steps
- Negotiation & Due Diligence – Both parties will finalize the definitive license agreement, covering confidentiality, milestone payments, and royalty terms.
- Regulatory Filings – PegBio will provide PDC with all necessary documentation for local product registration and pre‑marketing authorizations.
- Commercial Roll‑Out – Upon regulatory approval, PDC will initiate a multi‑channel marketing campaign targeted at endocrinology and obesity specialists across the MEA region.-Fineline Info & Tech